References
- MacCallum p, Tolhurst JC, Buckle G, Sissons HA. New mycobacterial infection in man: clinical aspects. J Path Bact 1948; 60: 93–102.
- World Health Organization. World Health Organization targets untreatable ulcer: report from the first international conference on Buruli ulcer control and research, Yamousoukro (Cote d'Ivoire). Inter Press Service, July 31, 1998.
- Horsburgh CR Jr, Meyers WM. Buruli ulcer. In: Horsburgh CR Jr, Nelson AM, eds. Pathology of emerging infections. Washington DC: American Society for Microbiology Press. 1997: 119-26.
- World Health Organization. Website: http://www.who.int/gtb-buruli/index.html
- Weir E. Buruli ulcer: the third most common Mycobacterial infection. Can Med Assoc J 2002; 166:1691.
- Amofah G, Bonsu F, Tetteh C, et al. Buruli ulcer in Ghana: results of a national case search. Emerging Infect Dis 2002; 8: 167–70.
- Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. App Environ Microbiol 2002; 68: 4623–8.
- Schroeder KH. Investigation in the relationship of Mycobacterium ulcerans to Mycobacterium buruli. Am Rev Resp Dis 1975; 111: 559–62.
- Srivastava A, Singh NB, Gupta SK. Prospective treat-ment for Mycobacterium ulcerans infection in rat and mice through combined therapy with rifampin and septran. Curr Sci 1984; 53: 487–8.
- Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical inci-sion. Am J Trop Med 1974; 23: 924–9.
- Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2001; 45: 3109–12.
- Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparatice in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium auium complex. Antimicrob Agents Chemother 1999; 43: 3001–4.
- Sheppard CC. The experimental disease that follows the injection of human leprosy bacilli into footpath of mice. J Exp Med 1960; 112: 445–54.
- Dhople AM. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in com-parison with rifampin. Arzneim Forsch/Drug Res 2001; 51: 501–5.
- Tomioka H, Sato K, Shimizu T, Sano C. Anti-Mycobacterium tuberculosis activities of new fluoro-quinolones in combination with other antituberculous drugs. J Infect 2002; 44: 160–5.
- Tomioka H, Sano C, Sato K, Shimizu T. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium auium complex. Inter J Antimicrob Agents 2002; 19: 139–45.
- Horsburgh CR Jr. Epidemiology of disease caused by nontuberculous mycobacteria. Semin Resp Infect 1996; 11: 244–51.
- World Health Organization. Buruli ulcer disease. Weekly Epidemiological Record 2002; 77: 271–5.
- Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MRW, Banerjee D. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000; 45: 231–3.
- Espey D, Djomand G, Diomande I, et al. Pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 2002; 6: 60–5.